153 related articles for article (PubMed ID: 20166525)
1. [Effect of Chai-ling-tang (Sairei-to) for methotrexate concentration degradation delay by methotrexate high-dose therapy].
Utsuki S; Oka H; Suzuki S; Sato S; Osawa S; Koizumi H; Miyajima Y; Fujii K
No Shinkei Geka; 2010 Feb; 38(2):133-7. PubMed ID: 20166525
[TBL] [Abstract][Full Text] [Related]
2. High-dose methotrexate therapy of childhood acute lymphoblastic leukemia: lack of relation between serum methotrexate concentration and creatinine clearance.
Joannon P; Oviedo I; Campbell M; Tordecilla J
Pediatr Blood Cancer; 2004 Jul; 43(1):17-22. PubMed ID: 15170885
[TBL] [Abstract][Full Text] [Related]
3. Early recognition of patients with decreased methotrexate clearance following high-dose methotrexate infusion therapy.
Ikeda H; Kihira K; Kuwata N; Arai S; Kimura Y; Miyake K; Kitaura T; Fujimura K; Kuramoto A; Fukuchi H
Hiroshima J Med Sci; 1996 Jun; 45(2):57-62. PubMed ID: 8810132
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of methotrexate in cerebrospinal fluid and serum after osmotic blood-brain barrier disruption in patients with brain lymphoma.
Zylber-Katz E; Gomori JM; Schwartz A; Lossos A; Bokstein F; Siegal T
Clin Pharmacol Ther; 2000 Jun; 67(6):631-41. PubMed ID: 10872645
[TBL] [Abstract][Full Text] [Related]
5. [Blood concentration monitoring during high-dose methotrexate treatment].
Jiao L; Zhou DB; Wang SJ; Zhang W; Duan MH; Li J; Han B; Xu Y; Zhao YQ; Shen T; Wang Q; Ye M
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2009 Oct; 31(5):564-6. PubMed ID: 19968071
[TBL] [Abstract][Full Text] [Related]
6. High-dose methotrexate for intraocular lymphoma.
Batchelor TT; Kolak G; Ciordia R; Foster CS; Henson JW
Clin Cancer Res; 2003 Feb; 9(2):711-5. PubMed ID: 12576439
[TBL] [Abstract][Full Text] [Related]
7. Weekly methotrexate-calcium leucovorin rescue: effect of alkalinization on nephrotoxicity; pharmacokinetics in the CNS; and use in CNS non-Hodgkin's lymphoma.
Pitman SW; Frei E
Cancer Treat Rep; 1977 Jul; 61(4):695-701. PubMed ID: 18282
[TBL] [Abstract][Full Text] [Related]
8. Late-onset delayed excretion of methotrexate.
Pauley JL; Panetta JC; Schmidt J; Kornegay N; Relling MV; Pui CH
Cancer Chemother Pharmacol; 2004 Aug; 54(2):146-52. PubMed ID: 15148625
[TBL] [Abstract][Full Text] [Related]
9. High-dose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcoma.
Crews KR; Liu T; Rodriguez-Galindo C; Tan M; Meyer WH; Panetta JC; Link MP; Daw NC
Cancer; 2004 Apr; 100(8):1724-33. PubMed ID: 15073863
[TBL] [Abstract][Full Text] [Related]
10. Prolonged accumulation of high-dose methotrexate in a case with large liver cysts.
Kawakami M; Omori H; Yamagami T; Soma T
Cancer Chemother Pharmacol; 2009 Aug; 64(3):619-22. PubMed ID: 19319534
[TBL] [Abstract][Full Text] [Related]
11. Primary central nervous system lymphoma: Phase I evaluation of infusional bromodeoxyuridine with whole brain accelerated fractionation radiation therapy after chemotherapy.
Dabaja BS; McLaughlin P; Ha CS; Pro B; Meyers CA; Seabrooke LF; Wilder RB; Kyritsis AP; Preti HA; Yung WK; Levin V; Cabanillas F; Cox JD
Cancer; 2003 Sep; 98(5):1021-8. PubMed ID: 12942571
[TBL] [Abstract][Full Text] [Related]
12. [Urinary beta 2-microglobulin as an indicator for impaired excretion of methotrexate].
Amino K; Kawaguchi N; Matsumoto S; Manabe J; Ishii Y; Tabata D; Machida M
Gan To Kagaku Ryoho; 1988 Nov; 15(11):3103-7. PubMed ID: 3056278
[TBL] [Abstract][Full Text] [Related]
13. Calculated versus measured creatinine clearance for dosing methotrexate in the treatment of primary central nervous system lymphoma.
Gerber DE; Grossman SA; Batchelor T; Ye X
Cancer Chemother Pharmacol; 2007 May; 59(6):817-23. PubMed ID: 16972068
[TBL] [Abstract][Full Text] [Related]
14. Treatment of central nervous system tumors with methotrexate.
Abelson HT; Kufe DW; Skarin AT; Major P; Ensminger W; Beardsley GP; Canellos GP
Cancer Treat Rep; 1981; 65 Suppl 1():137-40. PubMed ID: 6976830
[TBL] [Abstract][Full Text] [Related]
15. Determinants of the elimination of methotrexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer patients.
Joerger M; Huitema AD; van den Bongard HJ; Baas P; Schornagel JH; Schellens JH; Beijnen JH
Br J Clin Pharmacol; 2006 Jul; 62(1):71-80. PubMed ID: 16842380
[TBL] [Abstract][Full Text] [Related]
16. Severe complications after intrathecal methotrexate (MTX) for treatment of primary central nervous system lymphoma (PCNSL).
Weigel R; Senn P; Weis J; Krauss JK
Clin Neurol Neurosurg; 2004 Mar; 106(2):82-7. PubMed ID: 15003295
[TBL] [Abstract][Full Text] [Related]
17. Severe acute renal failure following high-dose methotrexate therapy in adults with haematological malignancies: a significant number result from unrecognized co-administration of several drugs.
de Miguel D; García-Suárez J; Martín Y; Gil-Fernández JJ; Burgaleta C
Nephrol Dial Transplant; 2008 Dec; 23(12):3762-6. PubMed ID: 18779628
[No Abstract] [Full Text] [Related]
18. Variability in dose intensity of high-dose methotrexate for nonmetastatic osteosarcoma.
Leavey PJ; Mantadakis E; Maale G
Pediatr Hematol Oncol; 2002; 19(7):483-9. PubMed ID: 12217194
[TBL] [Abstract][Full Text] [Related]
19. High-dose methotrexate: on the relationship of methotrexate elimination time vs renal function and serum methotrexate levels in 1164 courses in 264 Swedish children with acute lymphoblastic leukaemia (ALL).
Skärby T; Jönsson P; Hjorth L; Behrentz M; Björk O; Forestier E; Jarfelt M; Lönnerholm G; Höglund P
Cancer Chemother Pharmacol; 2003 Apr; 51(4):311-20. PubMed ID: 12721759
[TBL] [Abstract][Full Text] [Related]
20. Glucarpidase (carboxypeptidase g2) intervention in adult and elderly cancer patients with renal dysfunction and delayed methotrexate elimination after high-dose methotrexate therapy.
Schwartz S; Borner K; Müller K; Martus P; Fischer L; Korfel A; Auton T; Thiel E
Oncologist; 2007 Nov; 12(11):1299-308. PubMed ID: 18055849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
